Cardiol Therapeutics Inc. (TSX:CRDL), a biotechnology company developing proprietary formulations that will treat life-threatening diseases, was featured on BNN Bloomberg’s Market Call with Robert McWhirter. Cardiol uses CBD in its drug formulations due to CBDs anti-inflammatory properties, which could help reduce inflammation in human hearts. The company has teamed up with the University of Alberta to develop an encapsulation process that utilizes nanotechnology to enhance the compatibility of the drugs with the aqueous blood circulation, improve pharmacokinetics and increase drug concentration at the site of disease.
Cardiol also has a partnership with Noramco, a global leader in the manufacturing and supply of controlled drug substance APIs. Under its long-term, exclusive supply agreement, Cardiol will be able to manufacture and supply pure pharmaceutical CBD for Canada and Mexico. According to McWhirter, Cardiol believes that they will be able to produce one million grams of synthetic CBD within 2019, which will allow them to bypass provincial suppliers and licensed producers who are struggling to supply the Canadian cannabis market.
If Cardiol can produce one million grams of CBD and also negotiate supply agreements with Shoppers Drug Mart, for instance, McWhirter believes that the company will be able to meet their quota and start selling their drug formulation. He also thinks that Cardiol will be looking at establishing a US partner to capitalize on the hemp and CBD market there and meet the demand for cannabis-based therapies in both Canada and Mexico.
To view the full video, click here.